Acute and chronic postsurgical pain after living liver donation: Incidence and predictors

Susan Holtzman, Hance A. Clarke, Stuart A. McCluskey, Kara Turcotte, David Grant, Joel Katz – 5 July 2014 – Despite its prominence as a concern among potential surgical candidates, there is little information in the literature regarding the short‐ and long‐term pain experience after living liver donation. We undertook a prospective study to examine (1) the nature and incidence of acute and chronic pain after living donor hepatectomy and (2) the factors associated with an increased or decreased risk of adverse pain outcomes.

Ketanserin, a serotonin 2A receptor antagonist, alleviates ischemia‐related biliary fibrosis following donation after cardiac death liver transplantation in rats

Liping Chen, Geng Chen, Yibin Guo, Lei Liu, Li Xiao, Wenmei Fan, Bingyi Shi, Yeyong Qian – 5 July 2014 – Biliary fibrosis is a major complication after donation after cardiac death (DCD) liver transplantation. In this process, the roles of serotonin [5‐hydroxytryptamine (5‐HT)] and the 5‐HT2A receptor subtype are still unknown.

The transrepressive activity of peroxisome proliferator‐activated receptor alpha is necessary and sufficient to prevent liver fibrosis in mice

Michal Pawlak, Eric Baugé, William Bourguet, Karolien Bosscher, Fanny Lalloyer, Anne Tailleux, Corinna Lebherz, Philippe Lefebvre, Bart Staels – 4 July 2014 – Nonalcoholic fatty liver disease (NAFLD) is increasingly prevalent and strongly associated with central obesity, dyslipidemia, and insulin resistance.

Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial

Masatoshi Kudo, Guohong Han, Richard S. Finn, Ronnie T.P. Poon, Jean‐Frederic Blanc, Lunan Yan, Jijin Yang, Ligong Lu, Won‐Young Tak, Xiaoping Yu, Joon‐Hyeok Lee, Shi‐Ming Lin, Changping Wu, Tawesak Tanwandee, Guoliang Shao, Ian B. Walters, Christine Dela Cruz, Valerie Poulart, Jian‐Hua Wang – 4 July 2014 – Transarterial chemoembolization (TACE) is the current standard of treatment for unresectable intermediate‐stage hepatocellular carcinoma (HCC).

Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: Results from the WELCOME* study

Eleonora Scorletti, Lokpal Bhatia, Keith G. McCormick, Geraldine F. Clough, Kathryn Nash, Leanne Hodson, Helen E. Moyses, Philip C. Calder, Christopher D. Byrne, on behalf of the WELCOME Study Investigators – 4 July 2014 – There is no licensed treatment for nonalcoholic fatty liver disease (NAFLD), a condition that increases risk of chronic liver disease, type 2 diabetes, and cardiovascular disease.

Earlier presentation and application of curative treatments in hepatocellular carcinoma

Susanna V. Ulahannan, Austin G. Duffy, Timothy S. McNeel, Jonathan K. Kish, Lois A. Dickie, Osama E. Rahma, Katherine A. McGlynn, Tim F. Greten, Sean F. Altekruse – 4 July 2014 – The purpose of the study was to assess the use of curative therapies for hepatocellular carcinoma (HCC) in the population. HCC treatment patterns were examined in Surveillance, Epidemiology, and End Results (SEER) 18 registries (28% of U.S.).

Antagonistic interaction between Wnt and Notch activity modulates the regenerative capacity of a zebrafish fibrotic liver model

Mianbo Huang, Angela Chang, Minna Choi, David Zhou, Frank A. Anania, Chong Hyun Shin – 4 July 2014 – In chronic liver failure patients with sustained fibrosis, excessive accumulation of extracellular matrix proteins substantially dampens the regenerative capacity of the hepatocytes, resulting in poor prognosis and high mortality. Currently, the mechanisms and the strategies of inducing endogenous cellular sources such as hepatic progenitor cells (HPCs) to regenerate hepatocytes in various contexts of fibrogenic stimuli remain elusive.

Subscribe to